Merck logo

Merck

MKKGY | OTC
Chart Builder DCF Calculator
$32.78
-$0.29 (-0.88%)
At close: Nov 16, 2026, 3:53 PM ET
$32.73
-$0.05 (-0.15%)
After-hours: Nov 16, 2026, 3:37 PM ET
-0.88%

Rating

Updated: Nov 16, 2026
40.6
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #508/1021 (Top 50%)

Key Statistics

Market Data

Market Cap $71.26B
1D Range
32.76 33.18
52W Range
23.82 34.10

Valuation (TTM)

PE 25.78
PB 2.07
EV/EBITDA 11.47

Valuation (NTM)

Forward PE 17.67
Forward PEG 28.95
Price Target $0.00
Loading financial charts...

Profile

Merck KGaA is a leading German science and technology enterprise. Its business operations are strategically organized into three core divisions: Life Science, Healthcare, and Electronics. The Life Sci...

Sector Healthcare
Employees 62,461
IPO Date Nov 16, 2007
Fiscal Year n/a

Latest News

Merck KGaA (MKKGY) Q3 2026 Earnings Call Transcript

4 days ago · seekingalpha.com

Merck KGaA (MKKGY) Q3 2026 Earnings Call Transcript
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

29 days ago · wsj.com

Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates

3 months ago · zacks.com

Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development

4 months ago · businesswire.com

Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade

4 months ago · zacks.com

Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade
Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?

4 months ago · zacks.com

Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?
Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?

5 months ago · zacks.com

Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?
Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal

5 months ago · benzinga.com

Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal
Germany's Merck Is Buying Bio-Techne for $11.3 Billion

5 months ago · barrons.com

Germany's Merck Is Buying Bio-Techne for $11.3 Billion

Earnings

Latest Earnings
Nov 12, 2026
EPS
$0.51
Beat +2.60%
REV
$6.23B
Beat +1.81%
Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.